Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 5, Pages 603-612Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2020.1721463
Keywords
Androgenetic alopecia; 5-alpha-reductase inhibitors; finasteride; male pattern hair loss; minoxidil
Categories
Funding
- Leo Pharma
- Amgen Inc
- Novartis
- Merck Co.
- Celgene
- Coherus Biosciences
- Janssen Pharmaceuticals
- Regeneron
- MedImmune
- GlaxoSmithKline
- Cutanea
- Samson Clinical
- Boehringer Ingelheim
- Pfizer Inc
- Merck Sharp and Dohme
- Oncobiologics
- Roche
- Eli Lilly and Company
- Bayer Healthcare
Ask authors/readers for more resources
Introduction: Androgenetic alopecia is a common hair loss disorder affecting up to 80% of males by the age of 80. It is characterized by androgen related progressive thinning of hair in a defined pattern. It results in diminished self-esteem, reduced confidence and distress in affected men, irrespective of age or stage of baldness. An effective treatment for hair baldness is needed. Areas covered: In androgenetic alopecia, hair follicles undergo progressive miniaturization. Genetic factors and androgens are key role-players in disease pathogenesis. Herein the authors review the pharmacologic treatment of androgenetic alopecia, which involves 5 alpha reductase inhibitors, minoxidil and prostaglandins. Non-pharmacologic approaches are also explored. Expert opinion: Androgenetic alopecia progresses over time and although the current available medical treatments like finasteride and minoxidil are effective in arresting the progression of the disease, they allow only partial regrowth of hair at its best. Early treatment achieves a more optimal outcome. Non-pharmacologic treatments like PRP can be considered in patients refractory to medical treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available